We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Overexpression of Canonical Prefoldin Associates with the Risk of Mortality and Metastasis in Non-Small Cell Lung Cancer.
- Authors
Peñate, Xenia; Praena-Fernández, Juan Manuel; Romero Pareja, Pedro; Enguix-Riego, María del Valle; Payán-Bravo, Laura; Vieites, Begoña; Gomez-Izquierdo, Lourdes; Jaen Olasolo, Javier; Rivin del Campo, Eleonor; Reyes, Jose Carlos; Chávez, Sebastián; Lopez Guerra, Jose Luis
- Abstract
Canonical prefoldin is a protein cochaperone composed of six different subunits (PFDN1 to 6). PFDN1 overexpression promotes epithelial–mesenchymal transition (EMT) and increases the growth of xenograft lung cancer (LC) cell lines. We investigated whether this putative involvement of canonical PFDN in LC translates into the clinic. First, the mRNA expression of 518 non-small cell LC (NSCLC) cases from The Cancer Genome Atlas (TCGA) database was evaluated. Patients with PFDN1 overexpression had lower overall survival (OS; 45 vs. 86 months; p = 0.034). We then assessed the impact of PFDN expression on outcome in 58 NSCLC patients with available tumor tissue samples. PFDN1, 3, and 5 overexpression were found in 38% (n = 22), 53% (n = 31), and 41% (n = 24) of tumor samples. PFDN1, 3, and 5 overexpression were significantly associated with lower OS, lower disease-free survival (DFS), and lower distant metastasis-free survival (DMFS) for PFDN1 and 3 with a trend for PFDN5. In multivariate analysis, PFDN5 retained significance for OS (hazard ratio (HR) 2.56; p = 0.007) and PFDN1 for DFS (HR 2.53; p = 0.010) and marginally for DMFS (HR 2.32; p = 0.053). Our results indicate that protein response markers, such as PFDN1, 3, and 5, may complement mRNA signatures and be useful for determining the most appropriate therapy for NSCLC patients.
- Subjects
LUNG cancer risk factors; LUNG cancer prognosis; CANCER patients; GENE expression; LUNG cancer; MESSENGER RNA; MULTIVARIATE analysis
- Publication
Cancers, 2020, Vol 12, Issue 4, p1052
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers12041052